/C O R R E C T I O N/ - Hoshi Corporation/

Food and Healthcare Press Releases Thursday January 31, 2019 13:27
TOKYO--31 Jan--Kyodo JBN-AsiaNet/InfoQuest

In the news release, "Hoshi Corporation Starts Accepting Orders for Manufacturing Made-in-Japan Cosmetic Products by Fully Utilizing Bonded Cosmetic Factory" issued on 29-Jan-2019 by Hoshi Corporation, we are advised that the company's name in paragraph 15 was incorrect. "Hoshino" should read as "Hoshi". The full corrected release is as follows:

============================================================================
Hoshi Corporation Starts Accepting Orders for Manufacturing Made-in-Japan Cosmetic Products by Fully Utilizing Bonded Cosmetic Factory
Hoshi Corporation, the Tokyo-based OEM and ODM cosmetic company, has received a license from the Okinawa Regional Customs to operate Japan's first bonded cosmetic factory.

The company is strongly geared toward exporting OEM and ODM cosmetic products with its logistics base in Okinawa, as driven by growing international demand for made-in-Japan cosmetic products, mainly to Asian and Oceania countries. Currently Hoshi has been dealing with over 700 overseas clients.

The bonded cosmetic factory operation license has enabled the company to fully use its high manufacturing technology and quality to reduce costs and realize swift production, thereby offering you affordable manufacturing plans thanks to reduced tariff and storage costs.

Website: http://hoshicorp.jp/bondedfactory/
Devices available for access: PCs, mobile phones
  • Features of the Okinawa factory:

The Okinawa factory is located in the Global Logistics Center (Okinawa GLC) that is operated by Okinawa Yamato Transport Co., Ltd., a subsidiary of Yamato Holdings Co., Ltd., a major player in the logistic industry in Japan.

By operating the bonded factory in the Okinawa GLC area neighboring Naha International Airport, Hoshi can undertake filling, packaging, assembling operations and store materials in the bonded area.
  • Business advantages by fully utilizing Okinawa bonded factory:
TARIFF CUTS
You are NOT required to bear import duties imposed on cosmetic packages.
EXPRESS DELIVERY
The Okinawa factory is adjacent to Naha International Airport, allowing the lead time of import and export to be reduced.
GLOBAL LOGISTICS NETWORK
Make use of the global network of the Yamato transportation group, the largest logistic company in Japan.
RELIABLE MADE-IN-JAPAN BULK
High quality is assured by manufacturing under the Japanese GMP.
SMALL-LOT PRODUCTION
Accept manufacturing orders starting with a lot of 500 units
REDUCE STORAGE COST
Product storage inside the Okinawa GLC is available at low cost.
SUPPORT CROSS-BORDER EC BUSINESS
Hoshi supports cross-border e-commerce business by utilizing its logistic facility as your business hub.
  • Business flow by utilizing Okinawa bonded factory:
STEP 1
Transfer cosmetic bulk to Okinawa factory from Hoshi's domestic cosmetic manufacturing factories.
STEP 2
Import Korean or Taiwanese cosmetic packaging.
*Selected high-quality Taiwanese and Korean packaging can be imported at preferential tariff rates.
STEP 3
Fill cosmetic bulk into imported containers.
Final finishing process of assembling and packaging
STEP 4
Export to your clients/agents (a third country) without custom clearance.
Image: Comparison chart
https://kyodonewsprwire.jp/prwfile/release/M104323/201901212418/_prw_PI1fl_1S4u95E7.jpg
Geographical advantage of Okinawa, the southernmost island of Japan:
  • The only 24-hour operating customs clearance system in Japan
  • Less than 4 hours on flight to major Asian cities
  • Located at the center of the mass Asian market of 2 billion customers
Advantages of choosing Hoshi Corporation as your OEM partner:
  • Track record of exports to more than 20 countries
  • Decades of cosmetic OEM business experience with over 700 domestic and overseas clients, with over 20,000 product types handled
  • 4 manufacturing factories in Japan (Tokyo, Gunma, Saitama and Okinawa)
  • A proven and trusted service that has been steadily forged since Hoshi's founding
Company Profile
Name: Hoshi Corporation
Address: 31-2, Kanda Higashi Matsushita-Cho, Chiyoda-Ku, Tokyo, 101-0042, JAPAN
CEO: Tsuneo Hoshino
Founded: April 30, 1975
Capital: 80,000,000 yen
Business lines:
  • Sales of cosmetics, pharmaceuticals and health foods
  • Planning and sales of containers and packaging materials
  • Planning and contract manufacturing of cosmetics, pharmaceuticals and health foods
Source: Hoshi Corporation
AsiaNet 77289

Latest Press Release

Ansell Urges Global Priority For Supply Of Personal Protective Equipment

Ansell Limited, a global leader in protective solutions, is working with governments and health organizations worldwide to ensure unrestricted personal protective equipment (PPE) manufacture and supply is given top priority during the COVID-19...

Yiling Pharmacy Lianhua Qingwen has been approved by the Thai FDA

On March 31, Shijiazhuang Yiling Pharmaceutical Co., Ltd released a notice that they had received the approval of the modern herbal medicine registration issued by the Food and Drug Administration of Thailand. Lianhua Qingwen Capsule is recognized as in...

EW Nutrition Launches Industry-leading Webinar Series With Topical Antimicrobial Resistance Twin Sessions

Yesterday, German-based company EW Nutrition took a first step toward serving the animal production industry in these challenging times. The in-feed and on-farm solutions company has started a series of topical webinars on challenging issues such as...

Saxenda(R) Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda(R) (liraglutide 3.0 mg) in adolescents (aged 12–<18) with obesity.1 The study was accepted...

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson...

Related Topics